Intelligent Bio Solutions Inc., a company listed in the United States, has been informed by the Securities and Exchange Commission (SEC) that its Registration Statement on Form S-3, filed on March 18, 2024, will not undergo review by the commission. The SEC's communication, dated March 22, 2024, was addressed to Harry Simeonidis, the Chief Executive Officer of Intelligent Bio Solutions Inc. The SEC's letter reminded the company and its management of their responsibility for the accuracy and adequacy of their disclosures, irrespective of the SEC's review process. The SEC also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. Juan Grana, a contact person at the SEC, was mentioned for any further inquiries.

Intelligent Bio Solutions Inc., a company listed in the United States, has been informed by the Securities and Exchange Commission (SEC) that its Registration Statement on Form S-3, filed on March 18, 2024, will not undergo review by the commission. The SEC's communication, dated March 22, 2024, was addressed to Harry Simeonidis, the Chief Executive Officer of Intelligent Bio Solutions Inc. The SEC's letter reminded the company and its management of their responsibility for the accuracy and adequacy of their disclosures, irrespective of the SEC's review process. The SEC also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. Juan Grana, a contact person at the SEC, was mentioned for any further inquiries.